On Friday, a group of Australian researchers at Monash University in Melbourne found that an anti-parasitic drug killed corona virus (a single stranded RNA virus) cell culture within 48hours in the lab.
The antiparasitic drug is believed to act by not only binding to glutamate-gated chloride ion channels but also trigger the release of natural killer cells (NK cells) from MHC class I molecules on the cell surface which in turn leads to the detection and display of the viral peptide and their subsequent removal from the body.
A virus can either have a DNA or an RNA and outside a living cell, viruses crystalize.
The antiparasitic drug is effective in vitro against a broad range of viruses including influenza, zika virus and HIV virus.
The Australian researchers said they are working hard to figure out the dose that can be used in humans that will be effective.
We pray earnestly that this should have a headway.
Content created and supplied by: Osasbio (via Opera News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform See More